Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
A prospective cohort study called Clinnova-MS investigates AI and data science applications in health care for various forms of multiple scl…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis [NA]
A clinical trial update for NCT04009005 studying clinically isolated syndrome and relapsing-remitting multiple sclerosis; the study is curre…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis [NA]
This clinical trial update notes ongoing recruitment for a study assessing motor learning to improve fall resistance in relapsing-remitting …
-
EMA approval · 2025-12-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
The EMA authorised Teriflunomide Viatris for treatment of relapsing-relapsing multiple sclerosis, with Viatris Limited as the marketing auth…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis [Phase 2]
A Phase 2 multicenter trial is evaluating taurine as an adjunctive therapy for relapsing-remitting multiple sclerosis; the study is not yet …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-28EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited
The European Medicines Agency authorised Fingolimod Mylan, a generic version of fingolimod, for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Clinical trial update reporting the completion of a Special Drug-use Surveillance study for Kesimpta (ofatumumab) 20 mg subcutaneous injecti…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis [Phase 3]
This Phase 3 study evaluates multiple doses of natalizumab administered subcutaneously in Japanese participants with Relapsing-Remitting Mul…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
This document outlines a clinical trial update describing persistence with ozanimod treatment in relapsing-remitting multiple sclerosis (RRM…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Combined Motor Imagery and Vestibular Rehab for MS [NA]
This trial update describes a study evaluating combined motor imagery and vestibular rehabilitation for relapsing-remitting multiple scleros…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" [Phase 2]
Phase 2 clinical trial update evaluating HB-adMSCs for Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis; currently active but n…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis
Clinical trial update evaluating efficacy and safety of switching from MabThera to Rixathon in relapsing-remitting multiple sclerosis; the s…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update for RESET-MS, a Phase 1/Phase 2 study evaluating CABA-201 in relapsing-remitting and progressive multiple sclerosis, w…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS [Phase 2]
This clinical trial update describes a Phase 2 study of remibrutinib using magnetic resonance imaging in relapsing-remitting, secondary prog…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of PIPE-307 in relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial [NA]
This clinical trial update notes an active (not recruiting) study at Johns Hopkins comparing traditional versus early aggressive therapy for…
-
EMA approval · 2025-10-08EMA Authorised: Briumvi (ublituximab) — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency authorised Briumvi (ublituximab) for multiple sclerosis, including relapsing-remitting disease, with Neuraxpha…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This completed clinical trial describes switching from a first- or second-line disease-modifying therapy to Ozanimod in participants with Re…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis [Phase 2]
Phase 2 proof-of-concept trial of frexalimab (SAR441344) for relapsing-remitting multiple sclerosis; results have been posted, and the study…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis [NA]
This clinical trial update reports measurements of serum neurofilaments and GFAP in patients with relapsing-remitting and progressive multip…
-
EMA approval · 2025-09-25EMA Authorised: Riulvy (tegomil fumarate) — Neuraxpharm Pharmaceuticals S.L.
EMA authorised Riulvy (tegomil fumarate) for relapsing-remitting multiple sclerosis, with Neuraxpharm Pharmaceuticals S.L. as the marketing …
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks [Phase 4]
Phase 4 clinical trial evaluating whether an ABCG2 gene mutation influences teriflunomide exposure and safety in Chinese patients with relap…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis [Phase 3]
A Phase 3 randomized non-inferiority trial in relapsing-remitting multiple sclerosis compares ongoing anti-CD20 maintenance therapy with a d…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
This clinical trial update explains the concept of a durable effect for B-cell modulating therapies in relapsing-remitting multiple sclerosi…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis [Phase 3]
Phase 3 clinical trial evaluating the safety, tolerability, and efficacy of Peginterferon beta-1a (BIIB017) in pediatric participants with r…